Jan 3, 2021

Michael J. Fox Foundation awards QDTI grant to develop novel biomarker assays for Parkinson’s Disease

(June 2019) The Michael J. Fox Foundation, a leading organization in the field of research and treatment of Parkinson's Disease (PD) and related disorders, has awarded QDTI a research grant to develop an ultrasensitive assay for protein biomarkers associated with the Leucine-rich repeat kinase 2 (LRRK2) pathway. The LRRK2 pathway is a rapidly emerging area of PD diagnostic and therapeutic research, but new assays are needed to assist in PD drug development efforts. . QDTI will implement the protein biomarker assay on its novel all-magnetic detection platform.

We use cookies to recognize your repeat visits and preferences, analyze traffic on our site, and provide a better user experience. By using our site, you agree to the use of cookies to collect information. Please visit our Privacy Policy for more information and to understand how we use your data.